Navigation Links
Tranziger Announces Formation of Global Advisory & Development Team
Date:10/7/2009

LONDON and WASHINGTON, Oct. 7 /PRNewswire/ -- Tranziger Limited announced today the formation of its global advisory and business team to advise and assess companies in the life sciences and healthcare sectors to execute strategic transactions and realise and optimise value from their portfolios in these turbulent times. Tranziger Limited is headquartered in London, England, UK and has offices in Washington, DC and Edinburgh.

The Tranziger team will be attending the upcoming BioPartnering Europe conference from October 12-14 at the Queen Elizabeth Conference Centre in London.

Established in early 2009 by a group of senior, highly experienced international corporate business transactional professionals, Tranziger aims to help the managers and owners of small and mid-tier companies in the Biotechnology, Pharmaceutical, Diagnostics and Medical Technology sectors realise value in the currently challenging global economic environment. The group offers strategic transaction advisory and execution services including Mergers and Acquisitions, Corporate and Commercial Development, Corporate Partnering, technical due diligence, and strategic R&D consultancy. Tranziger also has a proprietary service for venture formation, development and commercialisation utilised by larger corporations, universities, government agencies and investment organizations.

Tranziger distinguishes itself from other groups by the fact that its team members originate from the same peer group as many of their prospective clients and deal partners, combining scientific acumen with seasoned experience at the transactional coalface. The group's geographical reach extends to Europe, North America and Asia Pacific, offering scope for a wider base of creative solutions and deal potential.

Dr. V. Paul Gerskowitch, Executive Chairman of Tranziger, said, "The global downturn has caused an intense reevaluation of business models and priorities. Very many newer spinout and mid-tier companies will struggle to survive, doomed by an inability to raise sufficient capital, partner or grow organically. At the same time, larger companies are increasingly staking claims earlier in all phases of technology development."

Neil J. Campbell, Managing Director, North America, said, "As investors focus ever more on those companies with quality data and revenue potential, the life science and healthcare sectors will likely selectively consolidate around those with top quality offerings. Increasingly, there will be a shift away from financial engineers to business builders. This will be brought about by the rise of so-called third age entrepreneurs and the need to derive more value from technology portfolios, thus spreading the risk. Proactive portfolio management and product/technology life cycle management, achieved via Tranziger's Portfolio Partnering model, will become an ever more urgent and value-driving activity for companies."

About Tranziger Limited

Tranziger was established in 2009 by a group of senior, highly experienced international corporate business transactional professionals. Tranziger aims to help the managers and owners of small and mid-sized companies in the Biotechnology, Pharmaceutical, Diagnostics and Medical Technology sectors realise value in the currently challenging global economic environment. The group offers strategic transaction advisory and execution services including Mergers and Acquisitions, Corporate and Commercial Development, Corporate Partnering, technical due diligence, and strategic R&D consultancy. Tranziger also has a proprietary service for venture formation, development and commercialization utilised by larger corporations, universities, government agencies and investment organizations. Further information about Tranziger can be found at www.tranziger.com.

    Contact:
    Tranziger, Limited
    +44 20 8663 3472
    Dr. Paul Gerskowitch, Executive Chairman
    gerskowitch@tranziger.com
    or
    Neil Campbell, Managing Director North American Operations
    +1 301 792 4345
    campbell@tranziger.com

    Tiberend Strategic Advisors, Inc.
    212-827-0020

    Andrew Mielach
    amielach@tiberendstrategicadvisors.com
    or
    Farrell Denby
    fdenby@tiberendstrategicadvisors.com

SOURCE Tranziger Limited


'/>"/>
SOURCE Tranziger Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Telesoft Announces Advanced Dispute Management Capabilities with Version 9.5
2. Cardiovascular Systems Announces Plans for Second Manufacturing Facility - New Facility Expands CSI's Capacity to Produce Peripheral Arterial Disease Systems
3. Health Department Announces First Doses of H1N1 Vaccine Arrive in Pennsylvania
4. Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports
5. NIH announces expansion of Rare Diseases Clinical Research Network
6. bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
7. One Source Industries Announces Promotion
8. The Symphony Guild Announces Artist Lineup for 2009 Event
9. Hanger Orthopedic Group, Inc. Announces Third Quarter 2009 Earnings Release Conference Call
10. China-Biotics, Inc. Announces Closing of Public Offering of Common Stock
11. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
(Date:8/18/2017)... ... ... “Steve the Snake”: an entertaining and moral-based short story about an unkind ... Harold Flash Haskins Jr., a husband, father and grandfather who served as a U.S. ... moral-based short stories for children and teens. My goal is to teach kids to ...
(Date:8/17/2017)... Waltham, Mass (PRWEB) , ... August 17, 2017 ... ... high use by health care organizations and considered extremely effective, very effective, or ... “Leading Physicians and Physician Leadership”. , NEJM Catalyst Insights Reports are based on ...
(Date:8/17/2017)... ... 17, 2017 , ... Industry CEOs, life science leaders, influential ... This off-the-record networking forum of the Boston Biotech Conference series will be held ... leaders and decision makers will discuss issues facing the development of anti-infective, antiviral, ...
(Date:8/17/2017)... City, Utah (PRWEB) , ... August 17, 2017 , ... ... share how to efficiently and effectively grow a dental practice in a competitive market ... hours of dental C.E. that could just transform you and your practice.” says Daniel ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced ... 30, 2017, and updated its financial outlook for fiscal ... the fiscal third quarter, Hill-Rom reported earnings of $0.09 ... in the prior-year period. These results reflect after-tax special ... primarily related to the non-cash write-down of assets associated ...
Breaking Medicine Technology: